Prognostic significance of survivin and Caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP

Scientific paper - Original scientific paper

• Author: Zdravko Mitrović
• Author: Ivana Ilić
• Author: Igor Aurer
• Author: Sandra Bašić-Kinda
• Author: Ivo Radman
• Author: Snježana Dotlić
• Author: Radmila Ajduković
• Author: Boris Labar
• Author's institution: University of Zagreb; School of Medicine
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences

Abstract (english)

Survivin is an inhibitor of apoptosis whose expression may be associated with inferior outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated without rituximab. Caspase-3 is the final caspase of the apoptotic cascade and its pattern of expression may also be related to patients' outcome. In this study we investigated immunohistochemical expression of survivin and caspase-3 (CPP32) in 57 patients with DLBCL treated with rituximab and CHOP (R-CHOP). According to previously published criteria, we separately analyzed correlation of different types of survivin expression with patients' outcome. Nuclear survivin was expressed in only 26% of cases, cytoplasmic survivin was expressed in 81% of cases while application of immunoreactivity scoring system yielded 58% of survivin positive cases. Caspase-3 was expressed in 77% of cases. There were no significant correlations between any type of survivin expression and response to treatment or survival of the patients. The expression of caspase-3 was also not associated with patients' outcome. We conclude that survivin and caspase-3 have no significant prognostic significance in patients with DLBCL treated with R-CHOP.

• Keywords (english): Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived / administration & dosage; Antibodies, Monoclonal, Murine-Derived / therapeutic use; Antineoplastic Combined Chemotherapy Protocols / therapeutic use; Biomarkers, Tumor / analysis; Caspase 3 / biosynthesis; Cyclophosphamide; Doxorubicin; Female; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins / biosynthesis; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse / drug therapy; Lymphoma, Large B-Cell, Diffuse / metabolism; Lymphoma, Large B-Cell, Diffuse / pathology; Male; Middle Aged; Neoplasm Staging; Prednisone; Prognosis; Rituximab; Survivin; Vincristine; Young Adult
• Language: english
• Publication type: Scientific paper - Original scientific paper
• Publication status: Published
• Peer review: Peer review
• Publication version: Accepted version
• Journal title: Pathology Oncology Research
• Numbering: vol. 17, no. 2, pp. 243-247
• p-ISSN: 1219-4956
• DOI: https://doi.org/10.1007/s12253-010-9304-4
• URN:NBN: urn:nbn:hr:105:221136
• Publication: 2011-06
• Document URL: https://doi.org/10.1007/s12253-010-9304-4
• Type of resource: Text
• Access conditions: Open access
• Created on: 2024-03-28 11:49:02